Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 2/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.40 |
| ▸ | MC5R | P33032 | 3/20 | 0.39 |
| ▸ | MC3R | P41968 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9775331 | 0.87 | L3MBTL1 (0.49) | L3MBTL1 | |
| SCHEMBL10761433 | 0.85 | L3MBTL1 (0.51) | L3MBTL1MC5RMC3RMC4R | |
| SCHEMBL9775314 | 0.82 | L3MBTL1 (0.52) | L3MBTL1MC5RMC3RMC4R | |
| SCHEMBL9543318 | 0.82 | L3MBTL1 (0.42) | L3MBTL1ALOX5KDM4AKDM4CKDM5A | |
| SCHEMBL8009232 | 0.82 | PPIB (0.41) | L3MBTL1ALOX5LTA4H | |
| SCHEMBL9775278 | 0.81 | KDM4A (0.52) | L3MBTL1KDM4A | |
| SCHEMBL23502347 | 0.81 | HTT (0.50) | L3MBTL1KDM4AKDM4C | |
| SCHEMBL22211256 | 0.81 | L3MBTL1 (0.47) | L3MBTL1ALOX5KDM4AKDM4CKDM5A | |
| SCHEMBL17109816 | 0.81 | HTT (0.63) | — | |
| SCHEMBL21023137 | 0.81 | CYP3A4 (0.41) | L3MBTL1ALOX5KDM4AKDM4CKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149046-B2 | Antibacterial sideromycins | Hsiri Therapeutics, Inc. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20190153010-A1 | ANTIBACTERIAL SIDEROMYCINS | Hsiri Therapeutics, LLC | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149046-B2 | Antibacterial sideromycins | SLC40A1, SFXN1, SLC39A14 | L3MBTL1 1599/4885ALOX5 2537/4885KDM4A 3153/4885 |
| US-20190153010-A1 | ANTIBACTERIAL SIDEROMYCINS | SLC40A1, SFXN1, SLC39A14 | L3MBTL1 1599/4885ALOX5 2537/4885KDM4A 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.